Hospital
Black River Health INC
Black River Health INC was paid $13.01M by Medicaid between Jan 2018 and Dec 2024, across 133 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoBLACK RIVER HEALTH INC
BLACK RIVER FALLS, WI 54615
BLACK RIVER FALLS, WI 54615
33aNPI1811940331assigned 05/18/2006
33bProvider typeCritical Access Hospital
28Total paid$13.01M
24GClaims201,822
24DCodes billed133
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Wisconsin
Rank by total paid#4 of 48
Median peer was paid$4.30M
This provider vs. median3.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 27,016 | $1.55M | |
| 2019 | 26,549 | $1.38M | |
| 2020 | 23,863 | $1.43M | |
| 2021 | 37,830 | $1.99M | |
| 2022 | 33,094 | $2.19M | |
| 2023 | 34,610 | $2.76M | |
| 2024incomplete | 18,860 | $1.72M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 13,404 | 10,907 | $2.84M |
| 96361 | Intravenous infusion, hydration; each additional hour | 19% | 5,526 | 3,483 | $2.49M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 7,359 | 5,668 | $1.57M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.4% | 8,811 | 7,418 | $963K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.2% | 3,764 | 2,986 | $681K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 5.1% | 2,946 | 1,742 | $663K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.4% | 2,879 | 1,700 | $577K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 4.1% | 4,348 | 3,681 | $533K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.7% | 1,694 | 1,128 | $486K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.3% | 2,610 | 2,105 | $294K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.1% | 986 | 782 | $271K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.6% | 2,482 | 1,926 | $210K |
121 more codes
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.6% | 2,017 | $206K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.6% | 1,146 | $202K |
| G0378 | Hospital observation service, per hour | <1% | 2,566 | $107K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 342 | $97K |
| 97597 | <1% | 611 | $73K | |
| 80053 | Comprehensive metabolic panel | <1% | 8,550 | $63K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 181 | $57K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 9,471 | $41K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 888 | $40K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 969 | $33K |
| 87631 | <1% | 302 | $31K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 333 | $29K |
| 84145 | <1% | 2,603 | $28K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 561 | $24K |
| 80320 | <1% | 1,132 | $22K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 108 | $21K |
| 84484 | <1% | 3,409 | $19K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 608 | $18K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,977 | $17K |
| 81001 | <1% | 6,522 | $17K | |
| 80306 | <1% | 1,414 | $17K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 43 | $14K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 285 | $13K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 2,927 | $13K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,667 | $12K |
| 83605 | <1% | 2,742 | $12K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,661 | $12K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 42 | $11K |
| 87040 | <1% | 2,766 | $11K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,418 | $10K |
| 83690 | <1% | 2,124 | $9K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 917 | $9K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 23 | $8K |
| 81025 | <1% | 926 | $7K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 98 | $7K |
| 85027 | <1% | 2,547 | $7K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,507 | $7K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 218 | $7K |
| 0003U | Infec agen detec ampli probe | <1% | 58 | $6K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 105 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,170 | $6K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,654 | $5K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 110 | $5K |
| 86140 | <1% | 1,430 | $4K | |
| 82962 | <1% | 2,593 | $4K | |
| 85007 | <1% | 2,292 | $4K | |
| 87186 | <1% | 801 | $3K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,622 | $3K |
| 0100U | <1% | 54 | $3K | |
| 84703 | <1% | 488 | $3K | |
| 80051 | <1% | 488 | $3K | |
| 85610 | <1% | 1,383 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 63 | $3K |
| 82565 | <1% | 835 | $3K | |
| 85378 | <1% | 516 | $2K | |
| 83735 | <1% | 768 | $2K | |
| 94760 | <1% | 5,184 | $2K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 22 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 106 | $2K |
| 83880 | <1% | 193 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 44 | $2K |
| 99201 | <1% | 13 | $2K | |
| 84520 | <1% | 542 | $1K | |
| 87081 | <1% | 96 | $1K | |
| 84460 | <1% | 372 | $1K | |
| 97162 | <1% | 52 | $1K | |
| 84450 | <1% | 327 | $1K | |
| 73610 | <1% | 61 | $962.13 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,178 | $958.38 |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 42 | $864.84 |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,369 | $800.90 |
| 80143 | <1% | 67 | $687.05 | |
| 80179 | <1% | 66 | $649.18 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 18 | $601.24 |
| 82247 | <1% | 161 | $470.13 | |
| 86618 | <1% | 38 | $416.50 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,611 | $406.12 |
| 87641 | <1% | 91 | $309.56 | |
| 51702 | <1% | 15 | $303.24 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 178 | $265.15 |
| 73030 | <1% | 28 | $234.82 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,632 | $192.21 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,399 | $184.29 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 108 | $182.50 |
| 87205 | <1% | 60 | $182.14 | |
| J3490 | Unclassified drugs | <1% | 6,511 | $179.90 |
| 87070 | <1% | 28 | $176.09 | |
| 80061 | Lipid panel | <1% | 12 | $124.56 |
| 96376 | <1% | 621 | $103.91 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 58 | $95.89 |
| 84075 | <1% | 28 | $93.32 | |
| 87077 | <1% | 24 | $83.50 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,969 | $79.05 |
| 82947 | <1% | 41 | $75.66 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,098 | $72.63 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,001 | $59.29 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 925 | $49.54 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,666 | $45.38 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 418 | $44.27 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,198 | $39.24 |
| 99219 | <1% | 55 | $25.52 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,926 | $17.28 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 34 | $1.83 |
| 99156 | <1% | 25 | $0.55 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 75 | $0.36 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 47 | $0.09 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 28 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 82 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 242 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 148 | $0.00 |
| A9270 | Non-covered item or service | 0% | 1,123 | $0.00 |
| J8597 | Antiemetic drug, oral, not otherwise specified | 0% | 237 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 73 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 21 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 13 | $0.00 |
| 99217 | 0% | 26 | $0.00 | |
| 94761 | 0% | 20 | $0.00 | |
| A4606 | Oxygen probe for use with oximeter device, replacement | 0% | 18 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 70 | $0.00 |
| 73630 | 0% | 16 | $0.00 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBUKOWSKI, CATHERINE (CFO)
| Provider | Location | Paid |
|---|---|---|
| Black River Health INC | Black River Falls, WI | $119K |
| MCHS Hospitals INC | Marshfield, WI | $46K |
| Lakeview Medical Center INC of Rice Lake | Chetek, WI | $8K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.